Isomab presents landmark data study supporting safety of angiogenic approaches in coronary artery disease

First comprehensive systematic review provides insights into the long-term safety profile of angiogenic approaches in coronary artery disease Data shows no evidence of increased cancer or retinopathy, resolving long-standing safety questions that have limited progress across the field...